Consort has completed the acquisition of Aesica. Aesica, a major European pharmaceutical CDMO, was established ten years ago to provide contract development and manufacturing services for finished dose and APIs.
Jon Glenn, Consort's Chief Executive Officer, said: "We are excited by the acquisition of Aesica which represents a very strong fit with our existing strategy of diversifying into adjacent markets and technologies to capture additional value in the drug/device supply chain. As one of Europe's leading pharmaceutical CDMOs, Aesica is highly complementary to Bespak's existing business and provides a number of clear strategic, competitive and value-enhancing benefits for the Enlarged Group."
Dr Robert Hardy, Chief Executive, Aesica said: “We are proud of what we have accomplished over the last decade, developing Aesica through a combination of organic growth, continuous process improvement and investment. We continue to see many exciting opportunities in the pharmaceutical contract manufacturing sector and we look forward to pursuing these under the ownership of Consort Medical plc. Our position as a pharmaceutical CDMO is now further strengthened in the global market place through the alignment Aesica has with Bespak, as part of the enlarged Consort Medical group. With our collective strengths, we will continue to provide high quality pharmaceutical contract development and manufacturing services internationally."